Taiwan · Delayed Price · Currency is TWD Mycenax Biotech Statistics
Total Valuation
Mycenax Biotech has a market cap or net worth of TWD 4.97 billion. The enterprise value is 5.64 billion.
| Market Cap | 4.97B |
| Enterprise Value | 5.64B |
Important Dates
The last earnings date was Tuesday, August 18, 2026.
| Earnings Date | Aug 18, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Mycenax Biotech has 207.23 million shares outstanding. The number of shares has increased by 0.75% in one year.
| Current Share Class | 207.23M |
| Shares Outstanding | 207.23M |
| Shares Change (YoY) | +0.75% |
| Shares Change (QoQ) | -0.37% |
| Owned by Insiders (%) | 2.67% |
| Owned by Institutions (%) | 0.19% |
| Float | 113.17M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.10 |
| PB Ratio | 3.53 |
| P/TBV Ratio | 3.64 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 40.54 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.91 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.61, with a Debt / Equity ratio of 0.66.
| Current Ratio | 0.61 |
| Quick Ratio | 0.24 |
| Debt / Equity | 0.66 |
| Debt / EBITDA | n/a |
| Debt / FCF | -68.70 |
| Interest Coverage | -10.94 |
Financial Efficiency
Return on equity (ROE) is -24.06% and return on invested capital (ROIC) is -8.76%.
| Return on Equity (ROE) | -24.06% |
| Return on Assets (ROA) | -6.86% |
| Return on Invested Capital (ROIC) | -8.76% |
| Return on Capital Employed (ROCE) | -19.29% |
| Weighted Average Cost of Capital (WACC) | 6.10% |
| Revenue Per Employee | 2.11M |
| Profits Per Employee | -986,840 |
| Employee Count | 387 |
| Asset Turnover | 0.25 |
| Inventory Turnover | 7.06 |
Taxes
| Income Tax | -7.81M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -32.96% in the last 52 weeks. The beta is 0.45, so Mycenax Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.45 |
| 52-Week Price Change | -32.96% |
| 50-Day Moving Average | 24.99 |
| 200-Day Moving Average | 30.01 |
| Relative Strength Index (RSI) | 40.43 |
| Average Volume (20 Days) | 132,865 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Mycenax Biotech had revenue of TWD 815.87 million and -381.91 million in losses. Loss per share was -1.84.
| Revenue | 815.87M |
| Gross Profit | -137.68M |
| Operating Income | -356.33M |
| Pretax Income | -389.72M |
| Net Income | -381.91M |
| EBITDA | -96.56M |
| EBIT | -356.33M |
| Loss Per Share | -1.84 |
Balance Sheet
The company has 264.94 million in cash and 927.73 million in debt, with a net cash position of -662.79 million or -3.20 per share.
| Cash & Cash Equivalents | 264.94M |
| Total Debt | 927.73M |
| Net Cash | -662.79M |
| Net Cash Per Share | -3.20 |
| Equity (Book Value) | 1.41B |
| Book Value Per Share | 6.82 |
| Working Capital | -561.95M |
Cash Flow
In the last 12 months, operating cash flow was 122.68 million and capital expenditures -136.18 million, giving a free cash flow of -13.51 million.
| Operating Cash Flow | 122.68M |
| Capital Expenditures | -136.18M |
| Depreciation & Amortization | 259.77M |
| Net Borrowing | 61.85M |
| Free Cash Flow | -13.51M |
| FCF Per Share | -0.07 |
Margins
Gross margin is -16.88%, with operating and profit margins of -43.68% and -46.81%.
| Gross Margin | -16.88% |
| Operating Margin | -43.68% |
| Pretax Margin | -47.77% |
| Profit Margin | -46.81% |
| EBITDA Margin | -11.83% |
| EBIT Margin | -43.68% |
| FCF Margin | n/a |
Dividends & Yields
Mycenax Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.75% |
| Shareholder Yield | -0.75% |
| Earnings Yield | -7.68% |
| FCF Yield | -0.27% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |